Organigram Reports Record Second Quarter Fiscal 2025 Results
Record gross revenue of $102.8 million and record net revenue of $65.6 million
Adjusted EBITDA¹ of $4.9 million
Net income of $42.5 million
Increase in anticipated Motif cost synergies to $15 million from $10 million
Total cash position of $83.4 million² and negligible debt
TORONTO–(BUSINESS WIRE)–Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada’s #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 (“Q2 Fiscal 2025”). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company’s acquisition of Motif Labs Ltd. (“Motif”) on December 6, 2024.
Q2 FISCAL 2025 HIGHLIGHTS
Gross revenue increased 79% to $102.8 million from $57.4 million in the same prior year period.
Net revenue increased 74% to $65.6 million from $37.6 million in the same prior year period.
International revenue increased 177% to $6.1 million from $2.2 million in the same prior year period.
Adjusted gross margin¹ increased to $21.9 million or 33%, from $11.6 million or 31% in the same prior year period.
Motif integration now expected to exceed original estimate of $10 million to provide approximately $15 million in annual cost synergies.
Adjusted EBITDA¹ increased to $4.9 million from $(1.0) million in the same prior year period.
Total cash position of approximately $83.4 million2 and negligible debt.
Maintained #1 market share position in Canada — #1 in vapes, #1 in pre-rolls, #1 in milled flower, #1 in hash, #1 in pure CBD gummies, #3 in edibles, #3 in dried flower3.
Acquired Collective Project Limited (“Collective Project”), marking entry into the fast-growing U.S. and Canadian beverage categories, with current distribution in 10 states and six provinces.
Closed third and final $41.5 million tranche of $124.6 million follow on investment from BAT.
“Our record revenue this quarter reflects the strength of our brands and our ability to execute across both domestic and international markets,” said Beena Goldenberg, Chief Executive Officer. “We are unlocking meaningful global growth potential — from increasing sales into key international markets like Germany, to our entrance into the U.S. hemp-derived beverage space. We expect this momentum to continue as we further strengthen our leadership in Canada and head into the seasonally stronger back half of the year.”
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.
Organigram Reports Record Second Quarter Fiscal 2025 Results
TORONTO–(BUSINESS WIRE)–Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada’s #1 cannabis company by market share, announced its record results for the second quarter ended March 31, 2025 (“Q2 Fiscal 2025”). The Q2 Fiscal 2025 results include a full quarter of consolidated financials from the Company’s acquisition of Motif Labs Ltd. (“Motif”) on December 6, 2024.
Q2 FISCAL 2025 HIGHLIGHTS
“Our record revenue this quarter reflects the strength of our brands and our ability to execute across both domestic and international markets,” said Beena Goldenberg, Chief Executive Officer. “We are unlocking meaningful global growth potential — from increasing sales into key international markets like Germany, to our entrance into the U.S. hemp-derived beverage space. We expect this momentum to continue as we further strengthen our leadership in Canada and head into the seasonally stronger back half of the year.”
Original press release
Get Our Sunday Newsletter
In This Article:
OGI, Organigram
Related News:
Canadian Cannabis Sales Sank Again in February
Looking at the Cannabis Meltdown by Sub-Sector
Canadian Cannabis Sales Sank in January
Another C$41.5 Million Invested in Organigram